» Articles » PMID: 1612480

Indomethacin Decreases Jejunal Fluid Secretion in Addition to Luminal Release of Prostaglandin E2 in Patients with Acute Cholera

Overview
Journal Gut
Specialty Gastroenterology
Date 1992 May 1
PMID 1612480
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Human cholera is associated with an increased luminal release of prostaglandin E2 (PGE2), but whether inhibition of increased PGE2 synthesis will reduce or control intestinal secretion is uncertain. 'Steady state' perfusions (10 ml/minute) in 12 patients with acute cholera, and repeat perfusions in nine of these patients during the convalescent phase were therefore performed using the triple lumen technique. The proximal jejunum was perfused with isotonic saline containing sodium-sulphobromophthalein as a non-absorbable marker. After intravenous administration of indomethacin (1.0 mg/kg) the jejunal net transfer of fluid and the jejunal flow rate of PGE2 were determined in 30 minute periods for 120 minutes after a 120 minute control period. Indomethacin decreased net fluid secretion (2.1 (0.3-4.2) v 4.5 (2.5-8.4) ml/hour x cm; medians, Q50 ranges, p less than 0.01) and the jejunal flow rate of PGE2 (1.5 (1.2-2.7) v 2.2 (1.4-4.9) ng/minute, p less than 0.05). The results of similar perfusion studies in 22 patients with acute cholera, used to establish the spontaneous time related change in fluid secretion, showed no significant change in net fluid transfer (3.5 (2.2-6.2) to 3.5 (2.6-11.6) ml/hour x cm, p greater than 0.25) over 240 minutes. These data provide further evidence in favour of the hypothesis that prostaglandins have a role in the cholera toxin induced intestinal fluid secretion in man.

Citing Articles

Convective washout reduces the antidiarrheal efficacy of enterocyte surface-targeted antisecretory drugs.

Jin B, Thiagarajah J, Verkman A J Gen Physiol. 2013; 141(2):261-72.

PMID: 23359285 PMC: 3557305. DOI: 10.1085/jgp.201210885.


Role of cyclooxygenase enzymes in a murine model of experimental cholera.

Gessell-Lee D, Popov V, Boldogh I, Olano J, Peterson J Infect Immun. 2003; 71(11):6234-42.

PMID: 14573642 PMC: 219558. DOI: 10.1128/IAI.71.11.6234-6242.2003.


Cholera toxin B subunit activates arachidonic acid metabolism.

Peterson J, Finkelstein R, Cantu J, Gessell D, Chopra A Infect Immun. 1999; 67(2):794-9.

PMID: 9916092 PMC: 96388. DOI: 10.1128/IAI.67.2.794-799.1999.


Cloning, characterization, and chromosomal mapping of a phospholipase (lecithinase) produced by Vibrio cholerae.

Fiore A, Michalski J, Russell R, Sears C, Kaper J Infect Immun. 1997; 65(8):3112-7.

PMID: 9234762 PMC: 175439. DOI: 10.1128/iai.65.8.3112-3117.1997.


Cholera toxin induces synthesis of phospholipase A2-activating protein.

Peterson J, Saini S, Dickey W, Klimpel G, Bomalaski J, Clark M Infect Immun. 1996; 64(6):2137-43.

PMID: 8675318 PMC: 174047. DOI: 10.1128/iai.64.6.2137-2143.1996.


References
1.
Bukhave K, Rask-Madsen J . Prostaglandin E2 in jejunal fluids and its potential diagnostic value for selecting patients with indomethacin-sensitive diarrhoea. Eur J Clin Invest. 1981; 11(3):191-7. DOI: 10.1111/j.1365-2362.1981.tb01840.x. View

2.
Wald A, Gotterer G, Rajendra G, Turjman N, HENDRIX T . Effect of indomethacin on cholera-induced fluid movement, unidirectional sodium fluxes, and intestinal cAMP. Gastroenterology. 1977; 72(1):106-10. View

3.
Cooper H, Levitan R, Fordtran J, INGELFINGER F . A method for studying absorption of water and solute from the human small intestine. Gastroenterology. 1966; 50(1):1-7. View

4.
Gots R, Formal S, Giannella R . Indomethacin inhibition of Salmonella typhimurium, Shigella flexneri, and cholera-mediated rabbit ileal secretion. J Infect Dis. 1974; 130(3):280-4. DOI: 10.1093/infdis/130.3.280. View

5.
JACOBY H, Marshall C . Antagonism of cholera enterotoxin by anti-inflammatory agents in the rat. Nature. 1972; 235(5334):163-5. DOI: 10.1038/235163a0. View